Although we don't think shareholders should simply follow insider transactions, logic dictates you should pay some attention to whether insiders are buying or selling shares. AI is about to change ...

HC Wainwright reaffirmed their buy rating on shares of Altimmune (NASDAQ:ALT – Free Report) in a research report sent to ...

Meeting to be held in Boston on April 9 and in New York on April 10 hosted by Piper Sandler.Stay Ahead of the Market: Discover outperforming ...

Viking (VKTX) stock, Structure (GPCR) stock and others surge after Pfizer’s obesity drug setback. Read more here.

In the last three months, 8 analysts have published ratings on Altimmune ALT, offering a diverse range of perspectives from bullish to bearish. The table below provides a concise overview of ...

Altimmune, Inc. (NASDAQ:ALT), a biopharmaceutical company focused on developing treatments for liver disease and immune modulating therapies, has been garnering significant attention from analysts ...

Altimmune, Inc. (NASDAQ:ALT), a biopharmaceutical company focused on developing treatments for liver disease and immune modulating therapies, has been garnering significant attention from analysts and ...